ET-1402 is under clinical development by Eureka Therapeutics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ET-1402’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ET-1402 overview
ET-1402 (JWATM-203) is under development for the treatment of hepatocellular carcinoma and hepatoblastoma. The therapeutic candidate is administered through intravenous, intratumoral or intrahepatic catheter. The therapeutic candidate acts by targeting cells expressing alpha fetoprotein (AFP). It is based on adaptive library panning for human antibodies (E-ALPHA) phage display platform and ARTEMIS platform. The therapeutic candidate is a autologous T cells transduced with lentivirus encoding an anti-AFP.
It was under development for the treatment of hepatocellular carcinoma.
Eureka Therapeutics overview
Eureka Therapeutics is a clinical-stage biotechnology company that focuses on the development of novel T-cell immunotherapies for the treatment of solid tumors and other malignancies. The company’s pipeline products include AFP which treats adult and pediatric liver cancer; GPC3 treats adult liver cancer; ROR1 for lung, breast and ovarian cancer; CD19 targets multiple solid tumors; MUC16 and WT1 which treats ovarian cancer; BCMA and GPRC5D for multiple solid tumors; CD19/CD22 treats B-cell leukemia and lymphoma. It collaborates to help develop and commercialize novel and complementary technologies. Eureka Therapeutics is headquartered in Emeryville, California, the US.
For a complete picture of ET-1402’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
